This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
SciClone Pharmaceuticals (Holdings) Résultats passés
Passé contrôle des critères 6/6
SciClone Pharmaceuticals (Holdings) has been growing earnings at an average annual rate of 11.2%, while the Pharmaceuticals industry saw earnings growing at 6% annually. Revenues have been growing at an average rate of 14.8% per year. SciClone Pharmaceuticals (Holdings)'s return on equity is 34.4%, and it has net margins of 35.6%.
Informations clés
11.2%
Taux de croissance des bénéfices
7.1%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 5.6% |
Taux de croissance des recettes | 14.8% |
Rendement des fonds propres | 34.4% |
Marge nette | 35.6% |
Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings
Apr 02Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today
Dec 14Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Jun 19SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's
May 31Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Feb 17Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Dec 02We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings
Oct 04SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jul 27An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued
Jun 02Ventilation des recettes et des dépenses
Comment SciClone Pharmaceuticals (Holdings) gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 3,156 | 1,122 | 870 | 171 |
30 Sep 23 | 3,017 | 1,038 | 839 | 159 |
30 Jun 23 | 2,878 | 953 | 808 | 147 |
31 Mar 23 | 2,814 | 904 | 781 | 135 |
31 Dec 22 | 2,750 | 855 | 753 | 124 |
30 Sep 22 | 2,706 | 844 | 738 | 134 |
30 Jun 22 | 2,662 | 833 | 724 | 145 |
31 Mar 22 | 2,590 | 878 | 726 | 140 |
31 Dec 21 | 2,518 | 923 | 729 | 134 |
30 Sep 21 | 2,259 | 837 | 742 | 114 |
30 Jun 21 | 2,089 | 779 | 753 | 85 |
31 Mar 21 | 2,004 | 766 | 703 | 80 |
31 Dec 20 | 1,919 | 754 | 653 | 75 |
30 Sep 20 | 2,001 | 817 | 615 | 77 |
31 Dec 19 | 1,708 | 615 | 579 | 88 |
31 Dec 18 | 1,409 | 535 | 533 | 77 |
31 Dec 17 | 1,213 | 20 | 728 | 83 |
30 Jun 17 | 1,166 | 294 | 586 | 96 |
31 Mar 17 | 1,146 | 258 | 587 | 111 |
31 Dec 16 | 1,112 | 213 | 591 | 105 |
30 Sep 16 | 1,060 | 246 | 544 | 88 |
30 Jun 16 | 1,072 | 257 | 550 | 72 |
31 Mar 16 | 1,034 | 183 | 515 | 82 |
31 Dec 15 | 1,021 | 191 | 509 | 80 |
30 Sep 15 | 991 | 130 | 488 | 129 |
30 Jun 15 | 913 | 102 | 458 | 124 |
31 Mar 15 | 879 | 186 | 442 | 88 |
31 Dec 14 | 836 | 156 | 426 | 90 |
30 Sep 14 | 774 | 133 | 429 | 29 |
30 Jun 14 | 790 | 140 | 467 | 28 |
31 Mar 14 | 770 | 68 | 499 | 57 |
31 Dec 13 | 769 | 66 | 510 | 49 |
30 Sep 13 | 780 | 78 | 541 | 35 |
Des revenus de qualité: 6600 has high quality earnings.
Augmentation de la marge bénéficiaire: 6600's current net profit margins (35.6%) are higher than last year (31.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 6600's earnings have grown by 11.2% per year over the past 5 years.
Accélération de la croissance: 6600's earnings growth over the past year (31.2%) exceeds its 5-year average (11.2% per year).
Bénéfices par rapport au secteur d'activité: 6600 earnings growth over the past year (31.2%) exceeded the Pharmaceuticals industry -1%.
Rendement des fonds propres
ROE élevé: 6600's Return on Equity (34.4%) is considered high.